Literature DB >> 19417860

Hypertension in diabetes: a call to action.

Norman R C Campbell1, Lawrence A Leiter, Pierre Larochelle, Sheldon Tobe, Arun Chockalingam, Richard Ward, Dorothy Morris, Ross Tsuyuki.   

Abstract

The Canadian Hypertension Education Program, Blood Pressure Canada, Canadian Hypertension Society, Heart and Stroke Foundation of Canada, Canadian Diabetes Association, College of Family Physicians of Canada, Canadian Pharmacists Association and the Canadian Council of Cardiovascular Nurses call on Canadian health care professionals to redouble efforts to help patients achieve treatment targets (blood pressure less than 130 mmHg systolic and less than 80 mmHg diastolic) in people with diabetes. Treatment of high blood pressure in people with diabetes results in large reductions in death and disability within a short period of time and needs to be a therapeutic priority. Achieving blood pressure targets requires sustained lifestyle modification, and three or more drugs including a diuretic are often required. Antihypertensive treatment in people with diabetes is one of the few medical treatments estimated to reduce overall health costs. The cost of treatment is less than the cost of complications prevented. Blood pressure needs to be assessed at all visits and home blood pressure assessment is encouraged. Management strategies need to include assessment and management of cardiovascular risks including smoking, unhealthy eating, physical inactivity, abdominal obesity, dyslipidemia as well as dysglycemia. The risks and benefits of acetylsalicylic acid in primary prevention of cardiovascular disease are uncertain in people with hypertension and diabetes. Intensive individualized lifestyle modification is recommended to prevent and treat hypertension, dyslipidemia, dysglycemia and other vascular risks in people with diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417860      PMCID: PMC2707170          DOI: 10.1016/s0828-282x(09)70493-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  47 in total

1.  Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations.

Authors:  J M Geleijnse; D E Grobbee; F J Kok
Journal:  J Hum Hypertens       Date:  2005-12       Impact factor: 3.012

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.

Authors:  Nicholas R Anthonisen; Melissa A Skeans; Robert A Wise; Jure Manfreda; Richard E Kanner; John E Connett
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

4.  The control of hypertension in persons with diabetes: a public health approach.

Authors:  D Bild; S M Teutsch
Journal:  Public Health Rep       Date:  1987 Sep-Oct       Impact factor: 2.792

5.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

6.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

7.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

Authors:  Fiona Turnbull; Bruce Neal; Charles Algert; John Chalmers; Neil Chapman; Jeff Cutler; Mark Woodward; Stephen MacMahon
Journal:  Arch Intern Med       Date:  2005-06-27

8.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Paul K Whelton; Joshua Barzilay; William C Cushman; Barry R Davis; Ekambaram Iiamathi; John B Kostis; Frans H H Leenen; Gail T Louis; Karen L Margolis; David E Mathis; Jamal Moloo; Chuke Nwachuku; Deborah Panebianco; David C Parish; Sara Pressel; Debra L Simmons; Udho Thadani
Journal:  Arch Intern Med       Date:  2005-06-27

9.  The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension.

Authors:  R M Touyz; N Campbell; A Logan; N Gledhill; R Petrella; R Padwal
Journal:  Can J Cardiol       Date:  2004-01       Impact factor: 5.223

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  14 in total

1.  2011 Canadian Hypertension Education Program recommendations: an annual update.

Authors:  Norm Campbell
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

2.  Hypertension revisited.

Authors:  Norm R C Campbell; Richard E Gilbert; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross T Tsuyuki; Stewart Harris
Journal:  Can Fam Physician       Date:  2012-06       Impact factor: 3.275

3.  2010 Canadian Hypertension Education Program recommendations: An annual update.

Authors:  Norm Campbell; Margaret Moy Lum Kwong
Journal:  Can Fam Physician       Date:  2010-07       Impact factor: 3.275

4.  Factors associated with hypertension prevalence, awareness, treatment and control among participants in the International Mobility in Aging Study (IMIAS).

Authors:  B Doulougou; F Gomez; B Alvarado; R O Guerra; A Ylli; J Guralnik; M V Zunzunegui
Journal:  J Hum Hypertens       Date:  2015-04-02       Impact factor: 3.012

5.  Blood pressure drugs have no mortality benefit in diabetic patients.

Authors:  Eddie Vos; Colin P Rose; Pierre Biron
Journal:  Can J Cardiol       Date:  2009-10       Impact factor: 5.223

6.  The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients.

Authors:  Milan Gupta; Hwee Teoh; Mahesh Kajil; Michelle Tsigoulis; Adrian Quan; Manoela Fb Braga; Subodh Verma
Journal:  Exp Clin Cardiol       Date:  2012

7.  Genetic predisposition to high blood pressure associates with cardiovascular complications among patients with type 2 diabetes: two independent studies.

Authors:  Qibin Qi; John P Forman; Majken K Jensen; Alan Flint; Gary C Curhan; Eric B Rimm; Frank B Hu; Lu Qi
Journal:  Diabetes       Date:  2012-07-24       Impact factor: 9.461

8.  Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey.

Authors:  Robert J Petrella; Dawn P Gill; Jean-Pascal Berrou
Journal:  Diabetes Metab Syndr Obes       Date:  2015-03-24       Impact factor: 3.168

9.  Genetic variation in CYP17A1 is associated with arterial stiffness in diabetic subjects.

Authors:  Soo Jin Yang; Seung-Tae Lee; Won Jun Kim; Se Eun Park; Sung Woo Park; Jong-Won Kim; Cheol-Young Park
Journal:  Exp Diabetes Res       Date:  2012-10-23

10.  Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009.

Authors:  Carmen de Burgos-Lunar; Rodrigo Jiménez-García; Miguel A Salinero-Fort; Paloma Gómez-Campelo; Angel Gil; Juan C Abánades-Herranz; Juan Cárdenas-Valladolid; Isabel del Cura-González
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.